Surgical Lymphoedema Treatment of Morbihan Disease: A Case Report.

Ann Plast Surg

From the Department of Plastic Surgery.

Published: May 2021

Morbihan disease is a rare condition characterized by persistent erythema and solid edema of the upper two thirds of the face, leading to visual impairment and significant esthetic disfigurement. The underlying etiology of the disease remains uncertain, but its correlation with lymphoedema has been conjectured. Definitive treatment options are also lacking, and most current topical, systemic, and surgical interventions provide transient or partial results.In this report, we describe a case of Morbihan disease in a 32-year-old man. He suffered from erythema and swelling over the left periorbital region for 6 years, and was diagnosed with Morbihan disease. As the edema was unresponsive to drug therapy, he was referred to our department. Indocyanine green lymphography was performed, and the diagnosis of facial lymphoedema was confirmed. Manual lymphatic drainage was not effective, so we proceeded with surgical procedures. Lymphaticovenous anastomosis was performed to improve lymphatic drainage, and blepharoplasty was performed to debulk the enlarged tissue of lymphoedema. The visual field improved significantly, and the patient remains free from reexpansion of the lesion during the 1-year follow-up.The surgical approach for lymphoedema treatment can be a viable option for severe Morbihan disease unresponsive to nonsurgical therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SAP.0000000000002797DOI Listing

Publication Analysis

Top Keywords

morbihan disease
20
lymphoedema treatment
8
lymphatic drainage
8
disease
6
morbihan
5
surgical
4
surgical lymphoedema
4
treatment morbihan
4
disease case
4
case report
4

Similar Publications

Novel prognostic factors and combination therapy outcomes in Morbihan disease: insights from an Asian population.

BMC Ophthalmol

November 2024

Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea.

Purpose: This study aimed to identify novel prognostic factors for Morbihan disease (MD) treatment outcomes and evaluate the efficacy of combination therapy in an Asian population, addressing the gaps in current understanding of this rare condition.

Methods: We conducted a retrospective analysis of MD patients diagnosed and treated at a tertiary hospital between 2017 and 2023. Patients received combinations of oral medications (tetracycline, isotretinoin, corticosteroids), topical treatments (tacrolimus, ivermectin), and intralesional steroid injections.

View Article and Find Full Text PDF
Article Synopsis
  • A woman in her thirties diagnosed with Morbihan disease experienced limited improvement despite years of treatment.
  • The introduction of Baricitinib led to a better health outcome for her, marking a significant shift in her treatment approach.
  • This case report is the first to explore Baricitinib for Morbihan disease, aiming to open up new potential therapies for the condition.
View Article and Find Full Text PDF
Article Synopsis
  • Morbihan's disease is a rare condition that leads to chronic swelling of the face, with unclear causes related to blood vessel and lymphatic system issues.
  • Traditional treatments are usually not effective, and there’s no widely accepted successful therapy for the condition.
  • A case study of a 17-year-old male showed improvement using a new combination treatment of cromolyn sodium nasal spray and oral montelukast, which had not been previously reported for this syndrome.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!